...vehicle. Next steps include advancing squalamine to clinical trials for viral infection. Ohr Pharmaceutical Inc.'s Evizon...

...to no signs of ocular toxicity or changes in intraocular pressure. In 2009, Ohr acquired Evizon...

...Evizon squalamine and trodusquemine ( MSI-1436 ) for $200,000 in August. Genaera halted development of Evizon...

...arterial hypertension (PAH) Genaera (GENR) Discontinues development of Lomucin to treat cystic fibrosis (CF), and squalamine lactate...

...compete with marketed treatments (see BioCentury, Jan. 8). Genaera Corp. (GENR), Plymouth Meeting, Penn. Product: Squalamine lactate...

...Lomucin, an orally absorbed antagonist of calcium-activated chloride channel (gob-5) to treat cystic fibrosis, and squalamine lactate...

...GENR discontinued studies of Lomucin talniflumate for cystic fibrosis and squalamine lactate to treat prostate cancer. The...

...PTP-1B) inhibitor in preclinical development to treat obesity. In January, GENR discontinued development of Evizon squalamine lactate...

...IL-9) in Phase II testing to treat asthma. In January, GENR discontinued development of Evizon squalamine lactate...

...ended 12/31/06 1/3/07 Genaera (GENR) 30% to ~25 $33.8 1.5 12/31/06 $22.8 Discontinues development of Evizon...